ALSO NOTED: Oscient gains approvable letter; Achillion sets IPO terms; and much more...

> The FDA has issued an approvable letter to Oscient Pharmaceuticals for Factive as a five-day treatment for community-acquired pneumonia. The developer says that the agency is looking for additional analysis of existing data and some clarifications, but isn't looking for a new trial. Oscient says it should be able to satisfy the FDA's requests in a few weeks. Oscient has already received approval for Factive as a seven-day therapy and is also seeking approval of Factive for acute sinus infections. Report

> Achillion Pharmaceuticals has set the terms of its IPO, looking to offer 4.5 million shares at a price of $14 to $16 each. Report

> The FDA has approved Alcon's ophthalmic solution for the reduction of elevated intraocular pressure. Report

> Charles River Laboratories International has been awarded a 10-year, $111.6 million contract by the National Cancer Institute, more than doubling the size of its current contract with NCI. Release

> Chutes & Ladders: The UK's SkyePharma says that two employees, communications director Peter Laing and corporate secretary Douglas Parkhill, are leaving the company by "mutual agreement." Report

> Matrix Laboratories said it signed a licensing agreement with Gilead for the manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate, an anti AIDS therapy. Release

And Finally…The CDC wants physicians to routinely test everyone from 13 to 64 for HIV. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.